Search Results
Your search for ,HIS matches 4562 pages
Showing 1901 - 1950Small Differences Found in Breast Cancer Recurrence With Partial-Breast vs Whole-Breast Irradiation
Partial-breast irradiation delivered over 5 to 10 days did not meet noninferiority criteria compared with whole-breast irradiation given over 5 to 7 weeks, according to 10-year results of the large NRG (NSABP B-39/RTOG 0413) trial presented at the 2018 San Antonio Breast Cancer Symposium.1 However, ...
Selected Abstracts From the San Antonio Breast Cancer Symposium
Each year, The ASCO Post asks Jame Abraham, MD, FACP, Director of the Breast Oncology Program at Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine, to offer his picks for the most important research presented at the 2018 San Antonio Breast Cancer ...
Essential Elements of an Effective Clinical Trials System: Business and Mission
Clinical trials aimed to improve health and quality of life are the cornerstone of progress in medicine. Support comes from academic medical centers, philanthropy, the National Institutes of Health (NIH), industry, or combinations thereof. Clinical trials need to be hypothesis-driven and address...
How Effective Is Talimogene Laherparepvec Injection in Metastatic Melanoma?
Injection of a genetically modified virus that induces the body’s own immune cells to attack metastatic melanoma effectively treated almost 40% of patients with tumors that could not be surgically removed, according to findings published by Louie et al in the Journal of the American...
Oncology Pioneer V. Shanta, MD, Has Long Championed Access to Quality Cancer Care
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, interviewed V. Shanta, MD, an internationally renowned oncologist and Chairperson of the Cancer Institute in Adyar, Chennai, India. Dr. Shanta has been with the Institute since 1955, holding several positions...
Emad S. Alnemri, PhD, Named National Academy of Inventors Fellow
EMAD S. ALNEMRI, PhD, Thomas Eakins Professor of Biochemistry and Molecular Biology at the Sidney Kimmel Cancer Center–Jefferson Health, has been named a fellow of the National Academy of Inventors. The 2018 fellows will be inducted in a ceremony in April 2019, at the Space Center Houston during...
Hastening the Development of Novel Therapies for Peripheral T-Cell Lymphomas
Peripheral T-cell lymphomas (PTCLs) make up a small fraction of all non-Hodgkin lymphomas—just 15%—in the United States.1 Although rare in the United States, the incidence of PTCL is common across Asia, the Caribbean, and sub-Saharan Africa. Although the reason for such global variation in PTCL is...
Community Oncology Alliance Elects New Officers and Board Members
THE COMMUNITY Oncology Alliance (COA) recently announced that Michael Diaz, MD, a practicing medical oncologist at Florida Cancer Specialists & Research Institute, has been elected President of COA. His 1-year term began on January 1, 2019. In addition, Kashyap Patel, MD, a practicing...
MD Anderson President Emeritus, John Mendelsohn, MD, Dies at Age 82
John Mendelsohn, MD, President Emeritus of The University of Texas MD Anderson Cancer Center, died of glioblastoma on January 7, 2019, at his home in Houston at age 82. He was an internationally acclaimed leader in the field of medicine and scientist whose research helped pioneer a new type of...
A Tribute to Arti Hurria, MD, FASCO, a Leader in Geriatric Oncology
The oncology community is deeply saddened by the untimely passing of Arti Hurria, MD, FASCO, a nationally regarded expert and advocate for elderly patients with cancer. Dr. Hurria died on November 7, 2018, in a traffic accident. At the time of her tragic death, Dr. Hurria was Director of the City...
Huntsman Cancer Institute Announces Construction of Proton Therapy Center
The Huntsman Cancer Institute (HCI) at the University of Utah recently began construction on a proton therapy center. The $31 million, 7,450 square-foot addition to the HCI’s Cancer Hospital will be the first proton therapy center in the Mountain West. The new center will be named in honor of...
Waun Ki Hong, MD, FACP, FASCO, Innovator in the Treatment of Head and Neck Cancer, Dies at 76
Waun Ki Hong, MD, FACP, FASCO, led numerous clinical trials showing that cisplatin-based chemotherapy and radiotherapy could effectively treat patients with cancer of the larynx while sparing their voice box. This seminal work also served as a model for organ-preservation strategies in many other...
A Visionary in Lymphoma, Bertrand Coiffier, MD, PhD, Dies at 71
Internationally renowned lymphoma expert Bertrand Coiffier, MD, PhD, died on January 2, 2019. He was 71. Dr. Coiffier published more than 500 papers and book chapters that garnered more than 50,000 literature citations, placing him among the top 1% of the most influential researchers globally. His ...
J. Evan Sadler, MD, PhD, Expert in Blood-Clotting Disorders, Dies at 67
Pioneering hematologist J. Evan Sadler, MD, PhD, an expert in the study and treatment of blood-clotting disorders, died December 13, 2018, at his home in Clayton, Missouri, following a brief illness. He was 67. His death was announced in a news item from the Washington University School of...
Adi Gazdar, MD, Cell Line Pioneer and Groundbreaking Pathologist, Dies
The International Association for the Study of Lung Cancer (IASCL) announced the death of Adi Gazdar, MD, of The University of Texas Southwestern Medical Center, Dallas, on December 29, 2018. Dr. Gazdar, a leader in lung cancer pathology, was a cell line pioneer and a groundbreaking pathologist....
New Regulations Require Better Communication With Patients Who Have Disabilities and Limited English Proficiency
Ever since President Barack Obama signed the Patient Protection and Affordable Care Act (ACA) into law on March 23, 2010, the nondiscrimination provision of the law, Section 1557, which prohibits discrimination on the basis of race, color, national origin, sex, age, or disability in certain health ...
AMMF–The Cholangiocarcinoma Charity, The Bili Project Foundation, Cholangiocarcinoma Foundation, and TargetCancer Foundation Join Forces to Advance Cholangiocarcinoma Research
For the first time, four nonprofits have joined together to support a Conquer Cancer Foundation of ASCO Young Investigator Award (YIA). Marina Baretti, MD, postdoctoral oncology fellow at Johns Hopkins University, is the recipient of the 2018 Conquer Cancer Foundation of ASCO/AMMF–The...
Facing Death: Having the Difficult Conversation With Your Patients
Michael Becker, a former CEO for two biotechnology companies, discusses his terminal head and neck cancer diagnosis and his message for oncologists: be proactive and, at the appropriate time, talk with your patients about death and dying. For more information about Michael Becker’s blog and his HPV ...
Louis M. Weiner, MD, Named National Academy of Inventors Fellow
THE NATIONAL ACADEMY OF INVENTORS (NAI) has named Louis M. Weiner, MD, Director of the Georgetown Lombardi Comprehensive Cancer Center, to its 2018 class of fellows. According to the National Academy of Inventors, election to NAI Fellow status is the “highest professional distinction accorded to...
IASLC Announces Dave Mesko, MBA, as New Chief Executive
THE INTERNATIONAL Association for the Study of Lung Cancer (IASLC) has announced Dave Mesko, MBA, as its new Chief Executive Officer. Mr. Mesko replaces Fred R. Hirsch, MD, PhD, who left IASLC after his 5-year term ended on October 31, 2018. Mr. Mesko will be primarily responsible for the overall ...
ASCO Remembers Charles A. Coltman, Jr, MD, FASCO, Cooperative Trial Pioneer and ASCO Past President
ASCO AND THE ONCOLOGY COMMUNITY mourn the loss of ASCO Past President and former SWOG leader Charles A. Coltman, Jr, MD, FASCO, President Emeritus, Cancer Therapy & Research Center, The University of Texas Health Science Center at San Antonio. Dr. Coltman died on November 28 at the age of 88....
Anil K. Rustgi, MD, Named Director of Herbert Irving Comprehensive Cancer Center
ANIL K. RUSTGI, MD, has been named Director of the Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center and NewYork-Presbyterian/Columbia University Irving Medical Center. Pending approval of the university’s trustees, Dr. Rustgi will serve as Professor of...
Stories of the Scientists Behind Immunotherapy
As the field of immunotherapy accelerates, so does the literature reporting on the path ahead. One of the newer books on the topic is A Cure Within: Scientists Unleashing the Immune System to Kill Cancer. It has a top-notch pedigree: the author, Neil Canavan, is a seasoned journalist with more than ...
Welcome Questions About Cervical Cancer Treatment Options
TWO STUDIES reported in The New England Journal of Medicine1,2 showed that patients with early-stage cervical cancer had reduced disease-free and overall survival when treated with minimally invasive radical hysterectomy vs open or radical hysterectomy. The findings of these studies have been...
Illustrating Genius
FOUR AND A HALF YEARS AGO, author Neil Canavan attended a scientific conference to learn what he could about the then-emerging field of immunotherapy for cancer. After a presentation by Zelig Eshhar, PhD, principal investigator in the Department of Immunology at the Weizmann Institute of Science...
Global Oncology Education and Professional Development: ASCO International’s Impact
ASCO is such a misnomer: the American Society of Clinical Oncology is far more than simply “American.” Over the past several years, I (a Canadian-born breast surgical oncologist, with an Indian-born mother and a Tanzanian-born father) have traveled to Zimbabwe, Bhutan, and the Philippines with this ...
Should I Have Lied?
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Optimal Duration of Checkpoint Inhibition in Melanoma Is No More Than 2 Years
For patients with advanced melanoma, the concept of treating to disease progression does not always apply. With many patients responding to checkpoint inhibition for years, when can treatment be safely discontinued? This important clinical question was addressed at the European Society for Medical...
Pembrolizumab Plus Chemoradiotherapy in HPV-Positive Head and Neck Cancer
The addition of pembrolizumab (Keytruda) to a chemoradiotherapy regimen yielded complete response rates of 85% in patients with human papillomavirus (HPV)-positive advanced squamous cell carcinoma of the head and neck. These findings from a phase Ib study were presented at the 2018 Society for...
Researchers at The University of Texas at Dallas Receive Funding for Assorted Cancer Projects
MORE THAN $4.5 million in new funding from state and federal agencies will support cancer-related research over the next 5 years at The University of Texas at Dallas. Two projects related to brain cancer, each totaling $200,000 over 2 years, recently received High-Impact/High-Risk Research...
AACR Remembers George H.W. Bush for Role in Cancer Research Support
The Board of Directors of the American Association for Cancer Research (AACR) released an announcement expressing sadness upon the passing of former President George H.W. Bush, on November 30 at the age of 94. Once elected, President Bush appointed Bernadine Healy, MD, in 1991 to lead the National ...
Frederick National Laboratory Names Leonard P. Freedman, PhD, Chief Science Officer
Leonard P. Freedman, PhD, has been named Chief Science Officer at the Frederick National Laboratory for Cancer Research. He joins the Frederick National Laboratory after 6 years as Founding President of the Global Biological Standards Institute, a nonprofit organization dedicated to advancing life ...
Prevent Cancer Foundation Award Goes to Big Tobacco Foe, Sharon Y. Eubanks, JD
One Friday afternoon in March 1999, Pat Glynn, an attorney and manager at the Department of Justice, called a colleague, Sharon Y. Eubanks, JD, to talk about a newly formed Tobacco Task Force. Full of enthusiasm, he described plans to bring a federal suit against the major tobacco companies on...
Low-Dose CT Lung Screening: New Developments Support Increased Quality, More Data, Deep Learning
Two years ago, Rick Avila, MS, Chief Executive Officer (CEO) of Accumetra, LLC, was using rolls of Scotch tape as a research tool. The Scotch tape was a phantom, or reference object, and his company was working with computed tomography (CT) lung screening sites around the world to determine the...
Cornelis Melief, MD, PhD, Receives 2018 ESMO Immuno-Oncology Award
The European Society for Medical Oncology (ESMO) has selected Cornelis Melief, MD, PhD, to receive the ESMO 2018 Immuno-Oncology Award in recognition of his work studying the interactions of the immune system with cancer. Dr. Melief is Professor Emeritus in Tumor Immunology at the Leiden...
Jonathan Chernoff, MD, PhD, Receives Grant to Investigate RAC1-Mutant Melanoma
Jonathan Chernoff, MD, PhD, Chief Scientific Officer and Stanley P. Reimann Chair in Oncology Research at the Fox Chase Cancer Center, has received a grant from the Melanoma Research Foundation to support research on RAC1-mutant melanoma. The grant will provide $200,000 over 2 years. With this...
Rishi Jain, MD, MS, DABOM, Joins Fox Chase GI Program
Rishi Jain, MD, MS, DABOM, has joined Fox Chase Cancer Center as Assistant Professor in the Gastrointestinal (GI) Medical Oncology Program. After graduating from Fox Chase/Temple University Fellowship Training Program, Dr. Jain moved on to the Gastrointestinal Medical Oncology Program at The Ohio...
Will the Trump Administration’s Plan to Reduce Cancer Drug Prices Work?
High drug prices are the number one health-care concern of many Americans. The average price of a cancer drug rose from less than $10,000/yr before 2000 to more than $170,000/yr in 2017.1-3 Between 1995 and 2013, the launch price of cancer drugs increased by 10% to 12% every year, and the average...
Expert Point of View: Eric P. Winer, MD, and Jame Abraham, MD
Commenting on the findings of the KATHERINE trial were Eric P. Winer, MD, Director of the Breast Oncology Program in the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute and the Thompson Senior Investigator in Breast Cancer Research andProfessor of Medicine at Harvard...
Scientific and Career Development Retreat: Networking and Collaborating With Promising Researchers
ASCO’s Conquer Cancer Foundation is committed to supporting the research and career development of young researchers through its Grants & Awards Program. On October 10–11, 2018, Conquer Cancer hosted its 4th Scientific and Career Development Retreat at ASCO headquarters in Alexandria,...
Role of Genomic Profiling in Younger Patients With Cancer
Although overall cancer survival rates continue to improve among all age groups in the United States—there are currently an estimated 15.5 million cancer survivors, and that number is expected to increase to 20.3 million by 20261—survival rates for adolescents and young adults with cancer (AYAs)...
No Benefit for Atezolizumab Plus Standard of Care for Maintenance in Colorectal Cancer Subset
ADDING ATEZOLIZUMAB (Tecentriq) to a fluoropyrimidine plus bevacizumab (Avastin) did not improve outcomes for patients with BRAF wild-type metastatic colorectal cancer enrolled in the umbrella MODUL trial.1 “Despite activity in other, immune-responsive tumor types, there was no improvement in...
Expert Point of View: Reinhard Dummer, MD
KEYNOTE-022’S invited discussant, Reinhard Dummer, MD, Professor of Dermatologic Oncology at the University Hospital Zurich Skin Cancer Center in Switzerland, told attendees, “We’ve been waiting for this small prospective randomized phase II trial, and the initial results appear very promising.”...
Using Tumor‑Infiltrating Lymphocytes to Treat Metastatic Melanoma
STEVEN A. ROSENBERG, MD, PhD, Chief of Surgery at the National Cancer Institute (NCI), began his pioneering research in adoptive cell transfer using interleukin (IL)-2 in the mid-1970s. His IL-2 studies were among the clinical trials that led to the first U.S. Food and Drug Administration approval ...
Beyond Checkpoint Inhibitors: Novel Immunotherapy Combinations With Antitumor Activity
THE 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting hosted a meeting of the minds of the world’s premier cancer immunologists. In addition to the cutting-edge laboratory science explored and presented at the meeting, numerous phase I clinical trials and a few phase II studies offered ...
A Battle With Leukemia: Part Memoir, Part Oncology History
BOOKMARK Title: Cancer Crossings: A Brother, His Doctors, and the Quest for a Cure to Childhood LeukemiaAuthor: Tim WendelPublisher: ILR PressPublication date: April 2018Price: $24.95, hardcover, 256 pages Tim Wendel is a journalist and author of several noted books, mostly concerning sports. In...
Lucio N. Gordan, MD, Named New Managing Physician and President of Florida Cancer Specialists
Florida Cancer Specialists (FCS) & Research Institute, LLC, the largest physician-owned oncology/hematology practice in the country, announced Lucio N. Gordan, MD, has been named Managing Physician and President. Dr. Gordan, a hematologist/oncologist, replaces Dr. William Harwin, who recently...
Denial’s Many Faces
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
The Skin Cancer Foundation Raises $600,000 at Gala
The Skin Cancer Foundation recently held its 22nd annual Gala at The Plaza Hotel in New York. The Champions for Change Gala is the Foundation’s signature fundraising event, and $600,000 was raised to support the organization’s educational campaigns, community programs, and research initiatives....
The Chemotherapy Foundation Innovation Gala
This year marks the 50th anniversary of the launch of The Chemotherapy Foundation. Founded by Ezra M. Greenspan, MD, in 1968, with the goal of advancing effective cancer treatments, The Chemotherapy Foundation helped propel the modern era of chemotherapy and the later development of targeted...
